Clicky

Adaptimmune Therapeutics plc(ADAP) News

Date Title
May 15 Adaptimmune Reports Q1 2024 Financial and Business Updates
May 15 Adaptimmune Secures up to $125 Million Debt Financing with Hercules Capital
May 1 Adaptimmune to Report Q1 2024 Financial and Business Updates on Wednesday, May 15, 2024
Apr 15 Adaptimmune (ADAP) Down on End of Collaboration With Roche
Apr 12 Strategic Collaboration between Adaptimmune and Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies Terminated
Apr 12 Roche, Adaptimmune part ways on cell therapy research
Mar 27 Results of Adaptimmune's SPEARHEAD-1 Trial with Afami-cel in Advanced Sarcomas Published in the Lancet
Mar 8 Adaptimmune Therapeutics Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag
Mar 7 Adaptimmune Therapeutics PLC Reports Q4 and Full Year 2023 Financial Results
Mar 7 Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q4 2023 Earnings Call Transcript
Mar 6 Adaptimmune Reports Q4/Full Year 2023 Financial Results and Business Updates
Jan 17 Adaptimmune Therapeutics (NASDAQ:ADAP shareholders incur further losses as stock declines 22% this week, taking three-year losses to 88%
Jan 16 Adaptimmune (ADAP) Surges More Than 80% in a Month: Here's Why
Dec 7 Positive week for Adaptimmune Therapeutics plc (NASDAQ:ADAP) institutional investors who lost 68% over the past year
Dec 6 Adaptimmune Completes Submission of Rolling Biologics License Application (BLA) to U.S. FDA for Afami-cel for the Treatment of Advanced Synovial Sarcoma
Nov 30 Adaptimmune (ADAP) Rises as GSK Transfers T-Cell Therapy IND
Nov 29 Adaptimmune Receives Transfer of IND for Lete-cel Program
Nov 13 Adaptimmune Therapeutics PLC (ADAP) Loses -28.34% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Nov 13 Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q3 2023 Earnings Call Transcript
Nov 9 Forecast: Analysts Think Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Business Prospects Have Improved Drastically